RT info:eu-repo/semantics/article
T1 T cell activity in successful treatment of chronic urticaria with omalizumab
A1 Barrios del Pino, Yvelise
A1 Sánchez Machín, Inmaculada
A1 Iglesias Souto, Javier
A1 Franco, Andrés
A1 Gonzalez, Ruperto
A1 Matheu, Víctor
A2 Medicina InternaDermatología y Psiquiatría
A2 Hospital Universitario de Canarias
AB Omalizumab, a humanized monoclonal anti-IgE antibody has the potential to alter allergen processing. Recently, ithas been postulated the assessment of PHA-stimulated adenosine triphosphate (ATP) activity as maker of CD4+ Tcells activity in peripheral blood cells. We present the case report of a 35-year-old woman with a history of chronicidiopathic urticaria and angioedema of 8 years of development with poor response to treatment. The patient waspartially controlled with cyclosporine at doses of 100 mg/12 h. However, she was still developing hives daily.Finally treatment with omalizumab was started at dose of 300 mg every 2 weeks. The patient experienced adecrease in urticarial lesions 2 days after starting therapy. We also evaluated the effects of omalizumab therapy onthe activity of peripheral blood CD4+ T cells from the patient, in order to determine the potential modification ofanti-IgE therapy on the process of antigen presentation-recognition. Activity of CD4+ cells by ATP release wasclearly increased demonstrating an enlarged CD4 activity. Omalizumab may be useful in the treatment of severechronic urticaria. ATP activity of peripheral blood CD4+ T cells might be a non-subjective method to assessOmalizumab activity.
YR 2011
FD 2011
LK http://riull.ull.es/xmlui/handle/915/35383
UL http://riull.ull.es/xmlui/handle/915/35383
LA en
DS Repositorio institucional de la Universidad de La Laguna
RD 13-may-2024